GlassScriptPhysician profile
Anthony Sesto
NPI 1699128801
$5,429.05
in general payments reported to CMS, 2019-2025
18 companies · $800 in 2025
The $800 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $440 · 2021: $663 · 2022: $1,084 · 2023: $1,237 · 2024: $654 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,191 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,944.93 | 2019-2025 | Air Optix, Precision 1, Dailies Aqua Comfort Plus |
| Johnson & Johnson Vision Care, INC. | $1,243.82 | 2019-2025 | Acuvue |
| Biotissue Holdings INC. | $726.50 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $456.28 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $205.00 | 2022-2025 | Miebo, Infuse, Alden Scleral Zenlens |
| Coopervision INC. | $192.33 | 2020-2025 | Misight Contact Lens, Clariti Contact Lens, Onefit Contact Lens |
| Sun Pharmaceutical Industries INC. | $176.70 | 2023-2025 | Cequa |
| Dompe US, INC. | $94.69 | 2021-2023 | Oxervate |
| Allergan, INC. | $70.97 | 2021-2022 | |
| Oyster Point Pharma, INC. | $66.35 | 2023-2024 | Tyrvaya |
| Glaukos Corporation | $64.97 | 2021 | |
| Apellis Pharmaceuticals, INC. | $46.36 | 2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $36.96 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $29.66 | 2024 | Xdemvy |
| Lombart Brothers, INC. | $28.92 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.83 | 2022 | |
| Sight Sciences, INC. | $17.26 | 2023 | Tearcare System |
| Quidel Corporation | $5.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Sesto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.